Advertisement

Medical Management of Peptic Ulcer Disease

  • Ashley H. VernonEmail author
Chapter

Abstract

Peptic ulcers remain a common pathology found in the USA. With the identification of Helicobacter pylori and nonsteroidal anti-inflammatory drugs (NSAIDs) as major contributing factors in the formation of peptic ulcers, targeted medical management has become much more effective in mitigating severe complications. The widespread use of H2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and H. pylori eradicating regimens has significantly decreased the need for surgical intervention. Due in large part to these advancements, there has also been a significant decline in the number of hospitalizations for peptic ulcer disease (PUD) in the USA decreasing from 222,000 to 156,000 (29.9%) from 1993 to 2006.

Keywords

Peptic ulcers Helicobacter pylori NSAID ulcers 

References

  1. 1.
    Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg. 2010;251:51–8.  https://doi.org/10.1097/SLA.0b013e3181b975b8.CrossRefGoogle Scholar
  2. 2.
    Espat NJ, Ong ES, Helton WS, Nyhus LM. 1990-2001 US general surgery chief resident gastric surgery operative experience: analysis of paradigm shift. J Gastrointest Surg. 2004;8:471–8.  https://doi.org/10.1016/j.gassur.2004.02.002.CrossRefPubMedGoogle Scholar
  3. 3.
    Gralnek IM, Barkun AN, Bardou M. Management of acute bleeding from a peptic ulcer. N Engl J Med. 2008;359:928–37.  https://doi.org/10.1056/NEJMra0706113.CrossRefPubMedGoogle Scholar
  4. 4.
    Schwesinger WH, Page CP, Sirinek KR, et al. Operations for peptic ulcer disease: paradigm lost. J Gastrointest Surg. 2001;5:438–43.CrossRefGoogle Scholar
  5. 5.
    Bardhan KD. Intermittent treatment of duodenal ulcer for long term medical management. Postgrad Med J. 1988;64(Suppl 1):40–6.PubMedGoogle Scholar
  6. 6.
    Leodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15:1949–58.CrossRefGoogle Scholar
  7. 7.
    Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99:1833–55.  https://doi.org/10.1111/j.1572-0241.2004.40014.x.CrossRefPubMedGoogle Scholar
  8. 8.
    Marcus EA, Inatomi N, Nagami GT, et al. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther. 2012;36:972–9.  https://doi.org/10.1111/apt.12059.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514–33.  https://doi.org/10.1111/apt.13497.CrossRefPubMedGoogle Scholar
  10. 10.
    Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol Hepatol. 2003;17:36B–40B.  https://doi.org/10.1155/2003/714124.CrossRefGoogle Scholar
  11. 11.
    Calvet X, García N, López T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603–9.  https://doi.org/10.1046/j.1365-2036.2000.00744.x.CrossRefPubMedGoogle Scholar
  12. 12.
    Flores HB, Salvana A, Ang ELR, et al. M1138 duration of proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Gastroenterology. 2010;138:S-340.  https://doi.org/10.1016/S0016-5085(10)61564-8.CrossRefGoogle Scholar
  13. 13.
    Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol. 2002;31:128–39.CrossRefGoogle Scholar
  14. 14.
    Malfertheiner P, Megraud F, O’Morain CA, et al (2016) Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. gutjnl-2016-312288.  https://doi.org/10.1136/gutjnl-2016-312288.
  15. 15.
    Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003;98:562–7.  https://doi.org/10.1111/j.1572-0241.2003.t01-1-07288.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Salazar CO, Cardenas VM, Reddy RK, et al. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012;17:382–90.  https://doi.org/10.1111/j.1523-5378.2012.00962.x.CrossRefPubMedGoogle Scholar
  17. 17.
    O’Connor A, Molina-Infante J, Gisbert JP, O’Morain C. Treatment of helicobacter pylori infection 2013. Helicobacter. 2013;18:58–65.  https://doi.org/10.1111/hel.12075.CrossRefPubMedGoogle Scholar
  18. 18.
    Liou J-M, Chen C-C, Chen M-J, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013;381:205–13.  https://doi.org/10.1016/S0140-6736(12)61579-7.CrossRefPubMedGoogle Scholar
  19. 19.
    Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587.  https://doi.org/10.1136/bmj.f4587.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Vakil N. Primary and secondary treatment for Helicobacter pylori in the United States. Rev Gastroenterol Disord. 2005;5:67–72.PubMedGoogle Scholar
  21. 21.
    Coxib and traditional NSAID Trialists (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79.  https://doi.org/10.1016/S0140-6736(13)60900-9.CrossRefGoogle Scholar
  22. 22.
    Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5:818–28, 828.e1–5; quiz 768.  https://doi.org/10.1016/j.cgh.2007.03.011.
  23. 23.
    Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302–8.CrossRefGoogle Scholar
  24. 24.
    Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug–associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med. 2000;160:1455–61.  https://doi.org/10.1001/archinte.160.10.1455.CrossRefPubMedGoogle Scholar
  25. 25.
    Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:719–26.  https://doi.org/10.1056/NEJM199803123381104.CrossRefPubMedGoogle Scholar
  26. 26.
    Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther. 2009;30:791–815.  https://doi.org/10.1111/j.1365-2036.2009.04105.x.
  27. 27.
    Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ. Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scand J Gastroenterol Suppl. 1995;210:9–14.PubMedGoogle Scholar
  28. 28.
    Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–13.  https://doi.org/10.7326/0003-4819-152-2-201001190-00009.CrossRefPubMedGoogle Scholar
  29. 29.
    Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107:345–60.  https://doi.org/10.1038/ajg.2011.480.CrossRefPubMedGoogle Scholar
  30. 30.
    Behrman SW. Management of complicated peptic ulcer disease. Arch Surg Chic Ill 1960. 2005;140:201–8.  https://doi.org/10.1001/archsurg.140.2.201.CrossRefGoogle Scholar
  31. 31.
    Tanaka R, Kosugi S, Sakamoto K, et al. Treatment for perforated gastric ulcer: a multi-institutional retrospective review. J Gastrointest Surg. 2013;17:2074–81.  https://doi.org/10.1007/s11605-013-2362-7.CrossRefPubMedGoogle Scholar
  32. 32.
    Crofts TJ, Park KG, Steele RJ, et al. A randomized trial of nonoperative treatment for perforated peptic ulcer. N Engl J Med. 1989;320:970–3.  https://doi.org/10.1056/NEJM198904133201504.CrossRefPubMedGoogle Scholar
  33. 33.
    Lau JY, Chung SC, Sung JJ, et al. Through-the-scope balloon dilation for pyloric stenosis: long-term results. Gastrointest Endosc. 1996;43:98–101.CrossRefGoogle Scholar
  34. 34.
    Kuwada SK, Alexander GL. Long-term outcome of endoscopic dilation of nonmalignant pyloric stenosis. Gastrointest Endosc. 1995;41:15–7.CrossRefGoogle Scholar
  35. 35.
    Cherian PT, Cherian S, Singh P. Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy. Gastrointest Endosc. 2007;66:491–7.  https://doi.org/10.1016/j.gie.2006.11.016.CrossRefPubMedGoogle Scholar

Copyright information

© SAGES 2019

Authors and Affiliations

  1. 1.Department of SurgeryBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations